Immunotherapy Combos Emerging in HCC Armamentarium
Published: Tuesday, Feb 18, 2020
Ghassan K. Abou-Alfa, MD
The treatment arsenal for advanced hepatocellular carcinoma (HCC) is expected to become more robust with PD-1/PD-L1 inhibitor–based combination therapies, according to Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center.
... to read the full story